MedPageToday -- GOTHENBURG, Sweden -- Early treatment with glatiramer (Copaxone) proved superior to later treatment in reducing conversion to multiple sclerosis in patients with a clinically isolated syndrome, researchers said here.
MedPageToday -- GOTHENBURG, Sweden -- Early treatment with glatiramer (Copaxone) proved superior to later treatment in reducing conversion to multiple sclerosis in patients with a clinically isolated syndrome, researchers said here.
